Study to Evaluate the Safety of Long-Term Use of Perforomist® (Formoterol Fumarate)

Dey Pharma

Status and phase: Completed; Phase 4

Conditions: COPD

Treatments: Drug: Perforomist, nebulization, COPD; Drug: Perforomist-Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT01488019

201-085

Details and patient eligibility

About

This study is a multi-center, randomized, placebo-controlled study to evaluate the long-term safety of Perforomist® inhalation therapy in subjects with Chronic Obstructive Pulmonary Disease (COPD). Individual participation is approximately 54 weeks, including 52 weeks of double-blind treatment.

Full description

None provided.

Enrollment: 1,071 patients

Sex: All

Ages: 40+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Able to understand the study requirements, provide written informed consent, and agree to abide by the study protocol and its restrictions
2. Male and female subjects at least 40 years of age with a medical diagnosis of COPD (i.e. persistent presence of dyspnea, cough or sputum production and a history of exposure to risk factors for the disease, such as tobacco smoke)
3. A current or prior history of at least 10 pack-years of cigarette smoking and a baseline breathlessness severity grade of >=2 (Modified Medical Research Council [MMRC] Dyspnea Scale Score) at randomization.
4. Women of child-bearing potential (WOCBP) must have a negative pregnancy test at the screening visit and agree to avoid becoming pregnant for the duration of study by using adequate contraception at study entry and throughout the trial. WOCBP will be advised to notify the Investigator of any change in their pregnancy status. WOCBP include: any female who has experienced menarche and is not post-menopausal (defined as amenorrhea for at least 12 consecutive months), or has not undergone surgical sterilization (hysterectomy, bilateral oophorectomy, or bilateral tubal ligation). Women who are using acceptable contraceptive medications or devices to prevent pregnancy or practicing abstinence or where partner is sterile (e.g., vasectomy) will be considered WOCBP.
5. Able to complete all aspects of the study through the end of the study, including all visits and tests, and self-administration of study medications.

Exclusion criteria

1. A medical diagnosis of asthma. Indication of a past history of asthma that is deemed inaccurate to a subject's current condition by the Investigator must be adequately addressed in the medical history.

2. Clinically significant abnormal chest x-ray (CXR) (within the past 12 months) diagnostic of active/significant disease other than COPD.

3. Evidence of any unstable or clinically significant hematopoietic, malignant, cardiovascular, hepatic, renal, neurologic, psychiatric, autoimmune disorder, or condition or disease other than COPD that, in the opinion of the Investigator, could place the subject at increased risk of complications, interfere with study participation, or confound any of the study objectives.

4. Subjects who had radiation or chemotherapy within the previous 12 months.

5. An abnormal laboratory test at screening deemed clinically significant and exclusionary by the Investigator.

6. A history of hypersensitivity to study drugs or their components, including albuterol rescue.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

1,071 participants in 2 patient groups, including a placebo group

Perforomist, nebulization, COPD

Experimental group

Description:

Active

Treatment:

Drug: Perforomist, nebulization, COPD

Perforomist-Placebo

Placebo Comparator group

Description:

Placebo

Treatment:

Drug: Perforomist-Placebo